false 0001878313 0001878313 2024-05-24 2024-05-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2024

 

 

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-41455   83-1495913

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

444 West Lake Street, Suite 1700  
Chicago, IL   60606
(Address of principal executive offices)   (Zip Code)

(312) 416-8592

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4©)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock   MAIA   NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 24, 2024, MAIA Biotechnology, Inc. (the “Company”) (NYSE American: MAIA) held its 2024 Annual Meeting of stockholders (the “Annual Meeting”). For more information on the proposals, which are described below, please refer to the Company’s definitive proxy statement, dated April 16, 2024, as filed by the Company with the Securities and Exchange Commission on April 16, 2024.

As of the record date of March 28, 2023, there were 20,581,469 shares of the Company’s common stock issued and outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, there were present, in person or by proxy, shareholders holding an aggregate of 14,610,088 shares of common stock, representing approximately 70.98% of the shares of common stock issued and outstanding and entitled to vote at the Annual Meeting; therefore a quorum was present. The following matters were submitted to a vote of stockholders at the Annual Meeting:

1. Election of Directors

Stockholders re-elected both of the Company’s Class II nominees for director for three-year terms expiring on the annual meeting of stockholders to be held in 2027 or until their successors are duly elected and qualified. Each of the nominees is currently serving as a member of our board of directors. The voting results were as follows:

 

Directors

    For    Withheld    Broker
Non-Votes

Vlad Vitoc

    10,891,641    87,131    3,631,316

Ramiro Guerrero

    10,573,719    405,053    3,631,316

Cristian Luput

    10,728,696    250,076    3,631,316

2. Ratification of Auditors

Stockholders ratified the appointment of Grant Thornton LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The voting results were as follows:

 

For

  

Against

  

Abstain

14,059,159   10,596   540,333

 

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 29, 2024

 

MAIA BIOTECHNOLOGY, INC.
By:  

/s/ Vlad Vitoc

Name:   Vlad Vitoc
Title:   Chief Executive Officer

 

3

v3.24.1.1.u2
Document and Entity Information
May 24, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001878313
Document Type 8-K
Document Period End Date May 24, 2024
Entity Registrant Name MAIA Biotechnology, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-41455
Entity Tax Identification Number 83-1495913
Entity Address, Address Line One 444 West Lake Street
Entity Address, Address Line Two Suite 1700
Entity Address, City or Town Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60606
City Area Code (312)
Local Phone Number 416-8592
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol MAIA
Security Exchange Name NYSEAMER
Entity Emerging Growth Company true
Entity Ex Transition Period false
Grafico Azioni Maia Biotechnology (AMEX:MAIA)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Maia Biotechnology
Grafico Azioni Maia Biotechnology (AMEX:MAIA)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Maia Biotechnology